Key statistics
On Friday, Amneal Pharmaceuticals Inc (2DT:STU) closed at 7.70, -1.28% below its 52-week high of 7.80, set on Sep 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.70 |
---|---|
High | 7.75 |
Low | 7.70 |
Bid | 7.70 |
Offer | 7.95 |
Previous close | 7.75 |
Average volume | 0.00 |
---|---|
Shares outstanding | 309.54m |
Free float | 129.11m |
P/E (TTM) | -- |
Market cap | 2.69bn USD |
EPS (TTM) | -0.6224 USD |
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Press releases
- Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration
- Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials
- Amneal Reports Second Quarter 2024 Financial Results
- Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules
- Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags
- Amneal to Report Second Quarter 2024 Results on August 9, 2024
- Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant
- Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar
- Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)
- Amneal Releases 2023 Environmental, Social and Governance Report
More ▼